Who is eligible for MIPS 102?

All patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy. Definitions: Risk Strata: Very Low, Low, Intermediate, High, or Very High Very Low/Low Risk – PSA 20 ng/mL; OR Gleason score 8 to 10/Gleason grade group 4-5; OR clinically localized stage T3 to T4 (adapted from the National Comprehensive Cancer Network, 2018). External beam radiotherapy – “external beam radiotherapy” refers to 3D conformal radiation therapy, intensity modulated radiation therapy, stereotactic body radiotherapy, and proton beam therapy.

Is MIPS 102 the same as MIPS 102?

Yes. CMS uses zero-padded three-digit Quality IDs (102) in official specifications, while clinicians often search for MIPS 102 or Quality ID 102 without the leading zero. Both refer to the same 2026 MIPS quality measure reported through the Quality Payment Program (QPP).

How do I report MIPS Measure 102 in 2026?

MIPS Measure 102 (Quality ID 102) is reported through the Quality Payment Program (QPP) as a MIPS Clinical Quality Measure (CQM) via qualified registry, eCQM, or Medicare Part B claims where applicable.

Is MIPS 102 a topped-out measure?

No, MIPS 102 is not topped out, meaning there is still meaningful performance variation across clinicians.

Measure ID: MIPS 102|Appropriate Use|2026 Performance Year

2026 MIPS Measure #102: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate

Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy who did not have a bone scan performed at any time since diagnosis of prostate cancer.

Process – High PriorityAppropriate UseOncologyUrology

Measure ID:MIPS 102 (Quality ID 102)

eCQM:CMS129v15

Collection:MIPS CQM, eCQM

Topped Out:No

View CMS Spec ↗

Measure Specification

Eligible Population

Any patient, regardless of age

ANDDiagnosis for prostate cancer

ANDPatient encounter during the performance period

WITHOUTEncounters conducted via telehealth: M1426

ANDLow (or very low) risk of recurrence, prostate cancer: G9706

Exclusions

None

Numerator

Patients who did not have a bone scan performed at any time since diagnosis of prostate cancer.

Reporting Codes

Performance Met:

3270FBone scan not performed prior to initiation of treatment nor at any time since diagnosis of prostate cancer

Performance Not Met:

3269FBone scan performed prior to initiation of treatment or at any time since diagnosis of prostate cancer

○ Exceptions:

M1427Documentation of medical reason(s) for performing a bone scan (including documented pain related to prostate cancer, salvage therapy, other medical reasons)

Documentation of system reason(s) for performing a bone scan (including bone scan ordered by someone other than the reporting physician) (3269F with 3P)

VBCA Insights

Why This Measure Matters

This measure ensures low-risk prostate cancer patients don't get bone scans, which rarely find disease in this group and expose them to unnecessary radiation. Bone scans are only useful for detecting spread in patients at higher risk; low-risk patients treated with radiation or surgery don't benefit. Reserve bone imaging for patients with elevated PSA after treatment, bone pain, or higher-grade disease. Avoiding unnecessary imaging improves outcomes by reducing harm and costs.

VBCA is a CMS-approved Qualified Clinical Data Registry (QCDR) that submits MIPS Measure 102 to the Quality Payment Program (QPP). Practices can report this measure as a MIPS Clinical Quality Measure (CQM), as an eCQM, or through qualified registry submission.

🧮MIPS Score Simulator

Estimate only — actual CMS scoring may vary based on reporting method, data completeness, and annual rule updates.

Your Performance Rate:%Benchmarks vary by collection type

💡 Tip: Enter your performance rate to compare MIPS points across all collection types. The same rate can score differently depending on how you submit.

Specialty Measure Sets

Oncology/Hematology Radiation Oncology Urology

Related Measures

Appropriate Use

MIPS 065: Appropriate Treatment for Upper Respiratory Infection (URI)MIPS 066: Appropriate Testing for Pharyngitis MIPS 116: Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis MIPS 261: Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness MIPS 277: Sleep Apnea: Severity Assessment at Initial Diagnosis MIPS 331: Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse)MIPS 332: Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate MIPS 335: Maternity Care: Elective Delivery (Without Medical Indication) at < 39 Weeks (Overuse)MIPS 360: Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose MIPS 364: Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT MIPS 405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions MIPS 406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients MIPS 416: Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt MIPS 421: Appropriate Assessment of Retrievable Inferior Vena Cava (IVC) Filters for Removal

Oncology

MIPS 143: Oncology: Medical and Radiation – Pain Intensity Quantified MIPS 144: Oncology: Medical and Radiation – Plan of Care for Pain MIPS 249: Barrett’s Esophagus MIPS 250: Radical Prostatectomy Pathology Reporting MIPS 395: Lung Cancer Reporting (Biopsy/Cytology Specimens)MIPS 396: Lung Cancer Reporting (Resection Specimens)MIPS 397: Melanoma Reporting MIPS 401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis MIPS 450: Appropriate Treatment for Patients with Stage I (T1c) – III HER2 Positive MIPS 453: Percentage of Patients who Died from Cancer Receiving Systemic Cancer-Directed MIPS 457: Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 MIPS 490: Appropriate Intervention of Immune-Related Diarrhea and/or Colitis in Patients Treated MIPS 491: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing MIPS 506: Positive PD-L1 Biomarker Expression Test Result Prior to First-Line Immune Checkpoint MIPS 507: Appropriate Germline Testing for Ovarian Cancer Patients MIPS 509: Melanoma: Tracking and Evaluation of Recurrence

Urology

MIPS 048: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in MIPS 050: Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years MIPS 250: Radical Prostatectomy Pathology Reporting MIPS 422: Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse MIPS 432: Proportion of Patients Sustaining a Bladder or Bowel Injury at the time of any Pelvic

Official Resources

📄 CMS Measure Specification (PDF)🔗 QPP Quality Payment Program

Clinical Rationale

Multiple studies have indicated that a bone scan is not clinically necessary for staging prostate cancer with a low (or very low) risk of recurrence and receiving primary therapy. For patients who are categorized as low risk, bone scans are unlikely to identify their disease. Furthermore, bone scans are not necessary for low-risk patients who have no history of bony involvement or if the clinical examination suggests no bony involvement.

Less than 1% of low risk patients are at risk of metastatic disease. While clinical practice guidelines do not recommend bone scans in low risk prostate cancer patients, overuse is still common. An analysis of prostate cancer patients in the Surveillance, Epidemiology and End Results Medicare database diagnosed from 2004-2007 found that 43% of patients for whom a bone scan was not recommended received it.

The analysis also found that the use of bone scans in low risk patients leads to an annual cost of $4 million dollars to Medicare. The overuse of bone scan imaging for low risk prostate cancer patients is a concept included on the American Urological Association’s (AUA) list in the Choosing Wisely Initiative as a means to promote adherence to evidence-based imaging practices and to reduce health care dollars wasted.

This measure is intended to promote adherence to evidence-based imaging practices, lessen the financial burden of unnecessary imaging, and ultimately to improve the quality of care for prostate cancer patients in the United States.

Clinical Recommendations

For symptomatic patients and/or those with a life expectancy of greater than 5 years, bone imaging is appropriate for patients with unfavorable intermediate-risk prostate cancer, high-risk and very-high-risk prostate cancer (Eastham, et al., 2022) (Evidence Level: Category 2A). Clinicians should not routinely perform abdominal pelvic computed tomography (CT) scan or bone scan in asymptomatic patients with low- or intermediate-risk prostate cancer.

(Expert Opinion) (American Society of Clinical Oncology, 2021) Don’t perform PET, CT, and radionuclide bone scans, or newer imaging scans in the staging of early prostate cancer at low risk for metastasis.

Implementation Notes

This measure contains one strata defined by a single submission criteria. This measure produces a single performance rate. For the purposes of MIPS implementation, this patient-periodic measure is submitted a minimum of once per patient per timeframe specified by the measure for the performance period. The most advantageous quality data code (QDC) will be used if the measure is submitted more than once for the specified timeframe.

If more than one QDC is submitted during the episode time period, performance shall be calculated by using the most advantageous QDC.

Report this measure through VBCA

Our QCDR handles measure selection, data validation, and submission—so you can focus on clinical performance.

Learn About Our QCDR →Talk to Us